Search
Emapalumab
go.drugbank.com/drugs/DB14724ApprovedInvestigational[L4840] As well, emapalumab was given the status of PRIME by the EMA.[L4845] … [A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority review and breakthrough therapy.
Dasatinib
go.drugbank.com/drugs/DB01254ApprovedInvestigationalBCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases. … [A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region
Synonyms: N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamideCategories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexSibeprenlimab
go.drugbank.com/drugs/DB18919ApprovedInvestigationalSibeprenlimab is a Proliferation Inducing Ligand (APRIL) blocker.[L54633] APRIL is a member of the tumour necrosis factor superfamily that regulates and modulates activated B cells. … [L54633] On November 25, 2025, sibeprenlimab was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression.[L54628]
Synonyms: Immunoglobulin g2, anti-(human proliferation-inducing ligand protein) (human monoclonal vis649 .gamma.2-chain), disulfide with human monoclonal vis649 .kappa.-chain, dimerTinzaparin
go.drugbank.com/drugs/DB06822ApprovedInvestigationalTinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa. … It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally.
Products: Logiparin Liq Sc 10000 Fxaiu/ml, INNOHEP INYECTABLE VIAL 2 MG 10.000 UI/ML.Imiquimod
go.drugbank.com/drugs/DB00724ApprovedInvestigationalImiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. … Miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma.
Mixtures: Imiquimod 5% / Levocetirizine Dihydrochloride 1% / Niacinamide 2%, Imiquimod 5% / Niacinamide 4%Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingCopper histidinate
go.drugbank.com/drugs/DB32041ApprovedMenkes disease is a rare, X-linked recessive disorder caused by pathogenic variants in the ATP7A gene, which encodes a copper transport protein essential for absorbing dietary copper and transporting it … [A275383,T903] In patients with the disease, defects in this transporter lead to the entrapment of copper in the intestinal lining and a subsequent inability to absorb it into the bloodstream, resulting
Elacestrant
go.drugbank.com/drugs/DB06374ApprovedInvestigational[L49334] Elacestrant binds to estrogen receptor-alpha (ERα) and acts as a selective estrogen receptor degrader (SERD) thanks to its ability to block the transcriptional activity of the ER and promote … of a SERD represents a therapeutic approach for the treatment of endocrine-resistant breast cancers.
Synonyms: (2R)-2-(2-(ethyl-((4-(2-(ethylamino)ethyl)phenyl)methyl)amino)-4-methoxy-phenyl)tetralin-6-ol, (6R)-6-(2-(ethyl((4-(2- (ethylamino)ethyl)phenyl)methyl)amino)-4-methoxyphenyl)- 5,6,7,8-tetrahydronaphthalen-2-olCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesTerfenadine
go.drugbank.com/drugs/DB00342ApprovedWithdrawnIn the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: (RS)-1-(4-tert-butylphenyl)-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}-butan-1-olInsulin lispro
go.drugbank.com/drugs/DB00046ApprovedInvestigationalInsulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. … Due to its duration of action of around 5 hours, Humalog is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersProducts: HUMALOG KWIKPEN®200 U / ML, ADMELOG®Telotristat ethyl
go.drugbank.com/drugs/DB12095ApprovedTelotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. … [L43342] It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitors